Disparities in care and outcomes for primary liver cancer in England during 2008–2018: a cohort study of 8.52 million primary care population using the QResearch database-Reference-Cited by-同舟云学术

Disparities in care and outcomes for primary liver cancer in England during 2008–2018: a cohort study of 8.52 million primary care population using the QResearch database

Published:2023-05 Issue: Volume:59 Page:101969
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Liao Weiqi^ORCID,Coupland Carol A.C.,Innes Hamish,Jepsen Peter,Matthews Philippa C.^ORCID,Campbell Cori,Barnes Eleanor,Hippisley-Cox Julia,Barnes Eleanor,Culver Emma,Fischer Roman,Hippisley-Cox Julia,Innes Hamish,Irving William L.,Jepsen Peter,Kelly Matt,Klenerman Paul,Liao Weiqi,Mann Derek,Marshall Aileen,Matthews Philippa C.,Pavlides Michael,Peters Rory J.R.,Pickles Elisabeth,Robineau James,Schuster-Böckler Benjamin,Song Chunxiao,Tomlinson Jeremy,Welberry Christopher

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Global burden of primary liver cancer in 2020 and predictions to 2040;Rumgay;J Hepatol,2022

2. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention;Liu;J Hepatol,2019

3. The mapping of cancer incidence and mortality trends in the UK from 1980-2013 reveals a potential for overdiagnosis;Oke;Sci Rep,2018

4. Cancer incidence and mortality projections in the UK until 2035;Smittenaar;Br J Cancer,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma;Oncogenesis;2024-09-12

2. Secular trends in the incidence, prevalence, and survival of primary liver cancer in the United Kingdom from 2000-2021: a population-based cohort study;2024-08-05

3. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom;Value in Health;2024-08

4. Dihydrotanshinone I targets ESR1 to induce DNA double-strand breaks and proliferation inhibition in hepatocellular carcinoma;Phytomedicine;2024-07

5. Inequities in primary liver cancer in Europe: The state of play;Journal of Hepatology;2024-04